Skip to main content
VCbacked
Log inGet Started

Enteral Access Technologies

Liverpool, United Kingdom

Enteral Access Technologies develops medical devices for safer nasogastric tube placement, featuring DoubleCHEK.

$659K raised
Nov 2025
Seed
Health CareManufacturingMedicalMedical Device

Top Investors

The Future FundBritish Design Fund

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Enteral Access Technologies

How much funding has Enteral Access Technologies raised?
Enteral Access Technologies has raised $659K in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Who are Enteral Access Technologies's investors?
Enteral Access Technologies's investors include The Future Fund, British Design Fund.
Where is Enteral Access Technologies headquartered?
Enteral Access Technologies is headquartered in Liverpool, United Kingdom.
What does Enteral Access Technologies do?
Enteral Access Technologies develops medical devices for safer nasogastric tube placement, featuring DoubleCHEK.
What stage is Enteral Access Technologies at?
Enteral Access Technologies is at the Seed stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Enteral Access Technologies — Funding & Investors." VCBacked, November 11, 2025, https://www.vcbacked.co/company/enteral-access-technologies. Accessed June 14, 2026.
APA
VCBacked. (2025). Enteral Access Technologies — Funding & Investors. Retrieved June 14, 2026, from https://www.vcbacked.co/company/enteral-access-technologies
Wikipedia (cite web)
{{cite web |title=Enteral Access Technologies — Funding & Investors |url=https://www.vcbacked.co/company/enteral-access-technologies |website=VCBacked |access-date=June 14, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Health Care

View all
Virtuoso Surgical
Nashville
Basata
Phoenix
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Sedivention
Munich$848K